

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 29, 2009

**VANDA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-51863**  
(Commission File No.)

**03-0491827**  
(IRS Employer Identification No.)

**9605 Medical Center Drive**  
**Suite 300**  
**Rockville, Maryland 20850**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(240) 599-4500**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events**

On May 29, 2009, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that it will hold its 2009 Annual Meeting of Stockholders on Thursday, August 27, 2009, in Rockville, Maryland. The record date for the Annual Meeting will be June 29, 2009. Only stockholders of record at the close of business on June 29, 2009 may vote at the meeting or any adjournment thereof. Vanda anticipates mailing its proxy statement in July 2009 to its stockholders of record, which proxy statement will include the time and location of the Annual Meeting, as well as a description of the matters to be considered. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release of Vanda Pharmaceuticals Inc. dated May 29, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VANDA PHARMACEUTICALS INC.

By: /s/ STEPHANIE R. IRISH

Name: Stephanie R. Irish

Title: Acting Chief Financial Officer and Treasurer

Dated: May 29, 2009



News Release

### **Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders**

ROCKVILLE, MD., May 29/PRNewswire-FirstCall/ — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2009 Annual Meeting of Stockholders on Thursday, August 27, 2009, in Rockville, Maryland. The record date for the Annual Meeting will be June 29, 2009. Only stockholders of record at the close of business on June 29, 2009 may vote at the meeting or any adjournment thereof. Vanda anticipates mailing its proxy statement in July 2009 to its stockholders of record, which proxy statement will include the time and location of the Annual Meeting, as well as a description of the matters to be considered.

#### **About Vanda**

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit <http://www.vandapharma.com>.

#### **Investor Contact:**

Stephanie R. Irish  
+1-240-599-4500  
[stephanie.irish@vandapharma.com](mailto:stephanie.irish@vandapharma.com)

#### **Media Contact:**

Cristina Murphy  
+1-240-599-4500  
[cristina.murphy@vandapharma.com](mailto:cristina.murphy@vandapharma.com)

Brad Miles  
BMC Communications Group, LLC  
+1-212-477-9007  
[brad@bmccommunications.com](mailto:brad@bmccommunications.com)